These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 3511286)

  • 1. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.
    Lamm DL; Stogdill VD; Stogdill BJ; Crispen RG
    J Urol; 1986 Feb; 135(2):272-4. PubMed ID: 3511286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment: a report of 2 cases.
    Stilmant MM; Siroky MB
    J Urol; 1986 Feb; 135(2):359-61. PubMed ID: 3511292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses.
    Stanisic TH; Brewer ML; Graham AR
    J Urol; 1986 Feb; 135(2):356-8. PubMed ID: 3511291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.
    Kelley DR; Haaff EO; Becich M; Lage J; Bauer WC; Dresner SM; Catalona WJ; Ratliff TL
    J Urol; 1986 Feb; 135(2):268-71. PubMed ID: 3511285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
    Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H
    Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.
    Rawls WH; Lamm DL; Lowe BA; Crawford ED; Sarosdy MF; Montie JE; Grossman HB; Scardino PT
    J Urol; 1990 Dec; 144(6):1328-30. PubMed ID: 2231917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of complications of bacillus Calmette-Guérin immunotherapy in the treatment of bladder cancer.
    Huang TC
    Ann Pharmacother; 2000 Apr; 34(4):529-32. PubMed ID: 10772442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer.
    Oates RD; Stilmant MM; Freedlund MC; Siroky MB
    J Urol; 1988 Oct; 140(4):751-4. PubMed ID: 3418796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
    J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.